Durlobactam

CHEMBL4298137 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

277.3 g/mol

LogP

-2.0

Phase

4

A beta-lactamase inhibitor used in combination with the antibiotic sulbactam to treat infections caused by carbapenem-resistant Acinetobacter baumannii. It protects the antibiotic from being broken down by bacterial enzymes.

Masse moléculaire

277,2600 g/mol

LogP

-2,00

TPSA

139,00 Å²

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1=C[C@@H]2CN(C(=O)N2OS(=O)(=O)O)[C@@H]1C(N)=O

InChI

InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1

Molecular Formula

C8H11N3O6S

HBD / HBA

2 / 6

Liaisons Rotatives

3

Atomes Lourds

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A beta-lactamase inhibitor used in combination with the antibiotic sulbactam to treat infections caused by carbapenem-resistant Acinetobacter baumannii. It protects the antibiotic from being broken down by bacterial enzymes.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Durlobactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298137. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 89851852. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Durlobactam sur PillFYI

Structure

Données Clés

Formule: C8H11N3O6S
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.